Translational Epigenetics Series Medical Epigenetics
Second Edition
Volume 29
Edited by
Trygve O. Tollefsbol
Distinguished Professor of Biology, Senior Scientist, Comprehensive Cancer Center, Comprehensive Center for Healthy Aging, University of Alabama at Birmingham, AL, United States
Academic Press is an imprint of Elsevier
125 London Wall, London EC2Y 5AS, United Kingdom
525 B Street, Suite 1650, San Diego, CA 92101, United States
50 Hampshire Street, 5th Floor, Cambridge, MA 02139, United States
The Boulevard, Langford Lane, Kidlington, Oxford OX5 1GB, United Kingdom
Copyright © 2021 Elsevier Inc. All rights reserved.
No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, or any information storage and retrieval system, without permission in writing from the publisher. Details on how to seek permission, further information about the Publisher’s permissions policies and our arrangements with organizations such as the Copyright Clearance Center and the Copyright Licensing Agency, can be found at our website: www.elsevier.com/permissions
This book and the individual contributions contained in it are protected under copyright by the Publisher (other than as may be noted herein).
Notices
Knowledge and best practice in this field are constantly changing. As new research and experience broaden our understanding, changes in research methods, professional practices, or medical treatment may become necessary.
Practitioners and researchers must always rely on their own experience and knowledge in evaluating and using any information, methods, compounds, or experiments described herein. In using such information or methods they should be mindful of their own safety and the safety of others, including parties for whom they have a professional responsibility.
To the fullest extent of the law, neither the Publisher nor the authors, contributors, or editors, assume any liability for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein.
Library of Congress Cataloging-in-Publication Data
A catalog record for this book is available from the Library of Congress
British Library Cataloguing-in-Publication Data
A catalogue record for this book is available from the British Library
ISBN 978-0-12-823928-5
For information on all Academic Press publications visit our website at https://www.elsevier.com/books-and-journals
Publisher: Andre Gerhard Wolff
Acquisitions Editor: Peter Linsley
Editorial Project Manager: Megan Ashdown
Production Project Manager: Sreejith Viswanathan
Cover Designer: Miles Hitchen
Typeset by STRAIVE, India
3.
4.
5. Behavioral medical epigenetics
6. Medical epigenetics and twins
J.C. Eissenberg
7.
Epigenetic biomarkers of disease
Patricia Chaves, Juan Luis Onieva, and Isabel Barragán
Section C Epigenetics of system disorders
9. Autoimmune disease and epigenetics
Sarah J. Blossom
prognosis, and drug response
prognosis, and drug response
8. Prognostic epigenetics
Adriana Fodor, Adriana Rusu, Gabriela Roman, Ramona Suharoschi, Romana Vulturar, Adela Sitar-Taut, and Angela Cozma
10. Epigenetics of pulmonary diseases
Akshaya Thoutam and Narasaiah Kolliputi
11. Cardiovascular disorders and epigenetics
Charbel Abi Khalil
14. Epigenetics in bone and joint disorders
N. Altorok, V. Nagaraja, and B. Kahaleh
12. Epigenomics of intestinal disease
S. Hashimoto-Hill, D.R. Kelly, and T. Alenghat
13. Epigenetics of skin disorders
15. Epigenetics of muscle disorders
Elisa Oltra
Epigenetic
Pathophysiology,
Genetic
Epigenetic
16. Reproductive disease epigenetics
Maricarmen Colon-Diaz, Alexander J. Jaramillo, Edwin Y. Soto, and Perla M. Elosegui
Section D
Multi-system medical epigenetics
18. Pediatric diseases and epigenetics
J.G. Hall and R. Weksberg
syndromes and disorders whose genes are involved in the processes and mechanisms of epigenetic regulation of
17. Epigenetics in ocular medicine
Beckwith–Wiedemann syndrome (aka Wiedemann–Beckwith syndrome)
syndrome (aka Silver–Russell syndrome)
The
21. Epigenetics in acute myeloid leukemia
Carmela Dell’Aversana, Cristina Giorgio, Francesco Paolo Tambaro, Giulia Sgueglia, and Lucia Altucci
19. Epigenetics of infectious diseases
K.L. Seib and M.P. Jennings
Helicobacter pylori and altered DNA methylation in infection and gastric cancer
Epigenetic modifications in bacterial pathogens
of DNA in bacterial pathogens
Dam N6-Adenine DNA methyltransferase
22. Epigenetic regulation in cancer metastasis
Guanying Bianca Xu, Huan Wang, Shijia Alexia Chen, and Hong Chen
20. Clinical utility of solid tumor epigenetics
Engin Demirdizen, Julian Taranda, and Sevin Turcan
23. Epigenetics in exercise science and sports medicine
A. Schenk, S. Proschinger, and P. Zimmer
Section E
Bioinformatics of epigenetic medicine
24. Machine learning in epigenetic diseases
Karyn G. Robinson and Robert E. Akins
26. Pharmacoepigenomics in neurodegenerative diseases
Nicoletta Nuzziello and Maria Liguori
pharmacoepigenomic
methylation as a pharmacoepigenomic target for NDDs 563
Histone posttranslational modifications affecting chromatin remodeling as pharmacoepigenomic targets for NDDs 565
as pharmacoepigenomic targets for NDDs 565 Epigenetic-modifying drugs for NDDs 568
Section F
Pharmacology of epigenetics
25. Epigenetics in toxicology and drug development
J. Tajbakhsh and J. Singh
Section G
Therapeutic epigenetics
27. Therapeutics and DNA methylation inhibitors
Shyamala C. Navada
Solid tumors 590
Epigenetic agents in combination—DNMT and HDAC inhibitors 591
Other DNMT inhibitors 591
Novel nucleoside DNMT inhibitors 591
Orally available 5-aza and 5-azadC 592
Nonnucleoside DNMT inhibitors 592
Conclusions 592
References 593
28. Histone deacetylase inhibitors in medical therapeutics
P. Chun
Introduction 597
Classification of histone deacetylases 597
Classification of HDAC inhibitors 598
HDAC inhibitors for the treatment of cancer 599
HDACs and cancer 599
Role of HDAC inhibitors in cancer 599
HDAC inhibitors and clinical outcomes 601
Combination therapy with immune checkpoint inhibitors 603
Conclusions 605
HDAC inhibitors for the treatment of heart diseases 605
Effects of HDAC inhibition on cardiac hypertrophy 606
Effects of HDAC inhibition on cardiac hypertension 608
Effects of HDAC inhibition on myocardial infarction 608
Effects of HDAC inhibition on heart failure 609
Effects of HDAC inhibition on atrial fibrillation 609
HDAC inhibitors for the treatment of kidney disease 609
Effects of HDAC inhibition on renal fibrosis 609
Effects of HDAC inhibitors on renal inflammation 610
HDAC inhibitors for the treatment of idiopathic pulmonary fibrosis 610
HDAC inhibitors for the treatment of inflammatory bowel disease 612
HDAC inhibitors for the treatment of rheumatoid arthritis 613
HDAC inhibitors for the treatment of schizophrenia 615
HDAC inhibitors for the treatment of Parkinson’s disease 616
Suppression of nuclear α-synuclein 616
Inhibition of neuroinflammation and oxidative stress 616
Increase in GDNF and BDNF 617
HDAC inhibitors for the treatment of diabetes mellitus 617
Effects of HDAC inhibitors on the pancreatic β-cells in diabetes 617
Effects of HDAC inhibitors in diabetic kidneys 618
Safety issues with the use of HDAC inhibitors 619
29. Sirtuins as NAD+-dependent deacetylases and their potential in medical therapy
Ashok Kumar and Mona Dvir-Ginzberg
30. Experimental approaches toward histone acetyltransferase modulators as therapeutics
D. Chen, H. Wapenaar, and F.J. Dekker
Challenges in the development of HAT modulators 682
Therapeutic possibilities of HAT modulators 683
HAT modulators in cancers 683
HAT modulators in inflammatory diseases and neurological diseases 683
Conclusion 684
References 684
31. Histone methylation modifiers in medical therapeutics
P. Trojer
Introduction 693
Enhancer of zeste homolog 2 (EZH2, KMT6A) 697
EZH2 functions in transcriptional repression 697
Discovery of EZH2 inhibitors 699
Therapeutic application of EZH2 inhibitors in NHL 699
Therapeutic application of EZH2 inhibitors in other cancer types 700
Disruptor of telomeric silencing like (DOT1L, KMT4) 702
DOT1L functions in transcription elongation 702
Discovery of DOT1L inhibitors 704
Therapeutic application of DOT1L inhibitors in AML 704
Lysine-specific demethylase 1 (LSD1, KDM1A) 705
LSD1 functions in activation and repression of transcription 705
Discovery of LSD1 inhibitors 707
Therapeutic application of LSD1 inhibitors in AML and MPNs 707
Therapeutic application of LSD1 inhibitors in solid tumors 708
Targeting other histone methylation modifiers 708
Conclusions 710
Glossary 712 Abbreviations 712 References 712
32. Modulation of noncoding RNAs (ncRNAs) and their potential role as therapeutics
Luciano Pirola, Oskar Ciesielski, Marta Biesiekierska, and Aneta Balcerczyk Introduction
33. Nutrients and phytonutrients as promising epigenetic nutraceuticals
Anait S. Levenson
34. Epigenetics of pain management
T. Louwies, A.C. Johnson, C.O. Ligon, and B. Greenwood-Van Meerveld
35. Precision medical epigenetics
Chang Zeng, Zhou Zhang, Xiaolong Cui, and Wei Zhang
36. Epigenetics and regenerative medicine
Devon
Ehnes, Shiri Levy, and Hannele
Ruohola-Baker
853 Epigenetic defects in aged tissues 853 Epigenetics and aging from a muscle regeneration perspective: Satellite stem cells 853
New insights into epigenetics and aging in other tissues can inform nascent fields: The salivary gland 856
Epigenetic dysregulation in developmental plasticity and non-age-related brain diseases 859
Age-related decline in cognition is linked to the deregulation of epigenetic marks 859
Epigenetic remodeling tools used in regenerative medicine therapeutics 861
Epigenetic chemical inhibitors 861 Epigenetic noncoding RNA used in regenerative medicine 861 Novel targeted epigenetic remodeler tools 862
of epigenetic remodelers in regenerative medicine 863
Epigenetic application tools in hESC and iPSC 863
37. Stem cell epigenetics in medical therapy
Baoli Cheng, Liqi Shu, Emily G Allen, and Peng Jin
Introduction 873
Stem cells 873
Epigenetics of stem cells 875
DNA methylation 875
Histone modifications 877
Noncoding RNA 878
RNA modifications 878
Therapeutic prospects of stem cells 879
Summary 880
Glossary 880
Abbreviation 881
References 881
Section H
Medical epigenetics: Future prospects
39. Epigenetics: Future prospective in human disorders and therapeutics
Shriram N. Rajpathak, Vinayak S. Biradar, and Deepti D. Deobagkar
Introduction 903
Epigenetics in stress and related disorders 903
Early life events and stress biology 903
Oxidative stress as a mediator for epigenetic changes 904
Stress and epigenetics machinery 904
Stress-related disorders 905
Epigenetics in human chromosomal disorders 907
Outline for an association between aneuploidy and epigenetic machinery 907
38.
The clinical landscape of HDAC inhibitors
A. Ganesan
Nucleosome modification and transcriptional regulation 885
One to eleven: The human zinc-dependent HDACs 885
Nuclear protein deacetylases HDAC1, HDAC2, and HDAC3 885
Cytoplasmic protein deacetylase HDAC6 886
Protein fatty acid deacylases HDAC8 and HDAC11 886
Polyamine deacetylase HDAC10 886
Pseudoenzymes HDAC4, HDAC5, HDAC7, and HDAC9 886
HDAC inhibitors—A pharmacological classification 886
Nonselective HDAC inhibitors 887
Nuclear isoform selective HDAC inhibitors 889
HDAC6 and HDAC8 isoform selective inhibitors 890
Dual mechanism HDAC inhibitors 891
Advanced clinical trials—Hematological cancers 892
Advanced clinical trials—Non-blood cancers 893
Advanced clinical trials—Beyond cancer 894
Summary 895
References 896
Autosomal aneuploidy conditions 909
Sex chromosomal aneuploidy 909
Non-coding RNAs as regulators in X monosomy and trisomy 913
Future perspective 914 References 914
40. Prospective advances in medical epigenetics
Jiali Deng, Mengying Guo, and Junjie Xiao
Introduction 919
Prospective advances of DNA methylation in medical epigenetics 921
Prospective advances of DNA methylation in vitiligo 923
Prospective advances of DNA methylation in liver 923
Prospective advances of DNA methylation age 926
Prospective advances of DNA methylation in neuron 926
Prospective advances of histone modification in medical epigenetics 927
Prospective advances of noncoding RNAs in medical epigenetics 928
International Human Epigenome Consortium and epigenetical precision medicine 930
Limitations 931
Prospect 931
Acknowledgments 932 References 932
Index 937
Contributors
Numbers in parenthesis indicate the pages on which the authors’ contributions begin.
Charbel Abi Khalil (197), Epigenetics Cardiovascular Lab, Research Department, Weill Cornell MedicineQatar, Doha, Qatar; Department of Genetic Medicine, Weill Cornell Medicine, New York, United States; Joan and Sanford I. Weill Department of Medicine, Weill Cornell Medicine, New York, United States
Robert E. Akins (513), Center for Pediatric Clinical Research and Development, Alfred I. duPont Hospital for Children, Nemours Children’s Health System, Wilmington, DE, United States
T. Alenghat (213), Division of Immunobiology and Center for Immunology and Tolerance, Cincinnati Children’s Hospital Medical Center; Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, United States
Emily G Allen (873), Department of Human Genetics, Emory University, Atlanta, GA, United States
N. Altorok (251), Division of Rheumatology and Immunology, Department of Internal Medicine, University of Toledo Medical Center, Toledo, OH, United States
Lucia Altucci (447), Department of Precision Medicine, University of Campania “Luigi Vanvitelli”, Naples, Italy
Aneta Balcerczyk (721), Department of Molecular Biophysics, Faculty of Biology and Environmental Protection, University of Lodz, Lodz, Poland
Isabel Barragán (117), Medical Oncology Service, Section of Immuno-Oncology, Hospitales Universitarios Regional y Virgen de la Victoria, Institute of Biomedical Research in Malaga (IBIMA), Málaga, Spain; Group of Pharmacoepigenetics, Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden
Marta Biesiekierska (721), Department of Molecular Biophysics, Faculty of Biology and Environmental Protection, University of Lodz, Lodz, Poland
Vinayak S. Biradar (903), Molecular Biology Research Laboratory, Department of Zoology, Savitribai Phule Pune University, Pune, India
Sarah J. Blossom (171), Department of Pharmaceutical Sciences, College of Pharmacy, University of New Mexico Health Science Center, Albuquerque, NM, United States
Patricia Chaves (171), Medical Oncology Service, Section of Immuno-Oncology, Hospitales Universitarios Regional y Virgen de la Victoria, Institute of Biomedical Research in Malaga (IBIMA); University of Málaga, Málaga, Spain
D. Chen (665), Department of Chemical and Pharmaceutical Biology, University of Groningen, Groningen, The Netherlands
Hong Chen (471), Department of Food Science and Human Nutrition; Division of Nutritional Sciences, University of Illinois at Urbana-Champaign, Urbana, IL, United States
Shijia Alexia Chen (471), Department of Food Science and Human Nutrition, University of Illinois at UrbanaChampaign, Urbana, IL, United States
Baoli Cheng (873), Department of Human Genetics, Emory University, Atlanta, GA, United States
P. Chun (597), College of Pharmacy, Inje University, Gimhae, South Korea
Oskar Ciesielski (721), Department of Molecular Biophysics, Faculty of Biology and Environmental Protection; The Bio-Med-Chem Doctoral School of the University of Lodz and Lodz Institutes of the Polish Academy of Sciences, University of Lodz, Lodz, Poland
Maricarmen Colon-Diaz (309), San Juan Bautista Medical School, Caguas, Puerto Rico
O.H. Cox (81), The Johns Hopkins Mood Disorders Center, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, United States
Angela Cozma (143), University of Medicine and Pharmacy; Department of 4th Internal Medicine, ClujNapoca, Romania
Xiaolong Cui (839), Department of Chemistry, University of Chicago, Chicago, IL, United States
F.J. Dekker (665), Department of Chemical and Pharmaceutical Biology, University of Groningen, Groningen, The Netherlands
Carmela Dell’Aversana (447), Institute for Experimental Endocrinology and Oncology “Gaetano Salvatore” (IEOS) – National Research Council (CNR); Department of Precision Medicine, University of Campania “Luigi Vanvitelli”, Naples, Italy
Engin Demirdizen (425), Neurology Clinic and National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany
Jiali Deng (919), Institute of Geriatrics (Shanghai University), Affiliated Nantong Hospital of Shanghai University (The Sixth People’s Hospital of Nantong), School of Medicine, Shanghai University, Nantong; Cardiac Regeneration and Ageing Lab, Institute of Cardiovascular Sciences, Shanghai Engineering Research Center of Organ Repair, School of Life Science, Shanghai University, Shanghai, China
Deepti D. Deobagkar (903), Molecular Biology Research Laboratory, Department of Zoology, Savitribai Phule Pune University, Pune, India
Mona Dvir-Ginzberg (633), Institute of Bio-Medical and Oral Research, Faculty of Dental Medicine, Hebrew University of Jerusalem, Jerusalem, Israel
Devon Ehnes (853), Institute for Stem Cell and Regenerative Medicine; Department of Biochemistry, School of Medicine, University of Washington, Seattle, WA, United States
J.C. Eissenberg (103), Edward A. Doisy Department of Biochemistry and Molecular Biology, Saint Louis University School of Medicine, Doisy Research Center, St Louis, MO, United States
Perla M. Elosegui (309), San Juan Bautista Medical School, Caguas, Puerto Rico
Adriana Fodor (143), University of Medicine and Pharmacy; Department of Diabetes, Nutrition and Metabolic Diseases, Cluj-Napoca, Romania
A. Ganesan (885), School of Pharmacy, University of East Anglia, Norwich, United Kingdom
Cristina Giorgio (447), Department of Precision Medicine, University of Campania “Luigi Vanvitelli”, Naples, Italy
Mengying Guo (919), Institute of Geriatrics (Shanghai University), Affiliated Nantong Hospital of Shanghai University (The Sixth People’s Hospital of Nantong), School of Medicine, Shanghai University, Nantong; Cardiac Regeneration and Ageing Lab, Institute of Cardiovascular Sciences, Shanghai Engineering Research Center of Organ Repair, School of Life Science, Shanghai University, Shanghai, China
J.G. Hall (377), Department of Medical Genetics and Pediatrics, University of British Columbia; BC Children’s Hospital, Vancouver, BC, Canada
S. Hashimoto-Hill (213), Division of Immunobiology and Center for Immunology and Tolerance, Cincinnati Children’s Hospital Medical Center; Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, United States
Mustapha Umar Imam (33), Centre for Advanced Medical Research and Training; Department of Medical Biochemistry, Faculty of Basic Medical Sciences, Usmanu Danfodiyo University, Sokoto, Nigeria
Maznah Ismail (33), Laboratory of Molecular Biomedicine, Institute of Bioscience, Universiti Putra Malaysia, UPM, Serdang, Selangor, Malaysia
Alexander J. Jaramillo (309), San Juan Bautista Medical School, Caguas, Puerto Rico
M.P. Jennings (407), Institute for Glycomics, Griffith University, Gold Coast, QLD, Australia
Peng Jin (873), Department of Human Genetics, Emory University, Atlanta, GA, United States
A.C. Johnson (817), Oklahoma Center for Neuroscience, University of Oklahoma Health Sciences Center; Veterans Affairs Health Care System; Department of Physiology, University of Oklahoma Health Sciences Center; Department of Neurology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States
B. Kahaleh (251), Division of Rheumatology and Immunology, Department of Internal Medicine, University of Toledo Medical Center, Toledo, OH, United States
D.R. Kelly (213), Division of Immunobiology and Center for Immunology and Tolerance, Cincinnati Children’s Hospital Medical Center; Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, United States
Alexander Koliada (11), Molecular Genetic Laboratory Diagen, Kyiv, Ukraine
Narasaiah Kolliputi (185), Division of Allergy and Immunology, Department of Internal Medicine, University of South Florida, Tampa, FL, Unites States
Ashok Kumar (633), Department of Biochemistry and Biophysics, University of Rochester, Rochester, NY, United States
R.S. Lee (81), The Johns Hopkins Mood Disorders Center, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, United States
Anait S. Levenson (741), Department of Veterinary Biomedical Sciences, College of Veterinary Medicine, Long Island University, Brookville, NY, United States
Shiri Levy (853), Institute for Stem Cell and Regenerative Medicine; Department of Biochemistry, School of Medicine, University of Washington, Seattle, WA, United States
C.O. Ligon (817), Oklahoma Center for Neuroscience, University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States
Maria Liguori (559), National Research Council, Institute of Biomedical Technologies, Bari Unit, Bari, Italy
Ji Liu (347), Department of Ophthalmology and Visual Science, Yale University School of Medicine, New Haven, CT, United States
T. Louwies (817), Oklahoma Center for Neuroscience, University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States
Qianjin Lu (231), Department of Dermatology, Second Xiangya Hospital of Central South University, Hunan Key Laboratory of Medical Epigenetics, Changsha, Hunan, People’s Republic of China
Shuaihantian Luo (231), Department of Dermatology, Second Xiangya Hospital of Central South University, Hunan Key Laboratory of Medical Epigenetics, Changsha, Hunan, People’s Republic of China
Oleh Lushchak (11), Department of Biochemistry and Biotechnology, Vasyl Stefanyk Precarpathian National University, Ivano-Frankivsk, Ukraine
B. Greenwood-Van Meerveld (817), Oklahoma Center for Neuroscience, University of Oklahoma Health Sciences Center; Veterans Affairs Health Care System; Department of Physiology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States
Rachel L. Miller (51), Icahn School of Medicine at Mount Sinai Hospital, New York, NY, United States
V. Nagaraja (251), Division of Rheumatology, Department of Internal Medicine University of Michigan, Ann Arbor, MI, United States
Shyamala C. Navada (585), Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, United States
Nicoletta Nuzziello (559), National Research Council, Institute of Biomedical Technologies, Bari Unit, Bari, Italy
Jessica Oh (51), Icahn School of Medicine at Mount Sinai Hospital, New York, NY, United States
Elisa Oltra (279), Department of Pathology, School of Health Sciences, Catholic University of Valencia, Valencia, Spain
Juan Luis Onieva (117), Medical Oncology Service, Section of Immuno-Oncology, Hospitales Universitarios Regional y Virgen de la Victoria, Institute of Biomedical Research in Malaga (IBIMA), Málaga, Spain
Der Jiun Ooi (33), Department of Oral Biology & Biomedical Sciences, Faculty of Dentistry, MAHSA University, Jenjarom, Selangor, Malaysia
Luciano Pirola (721), Cardiology, Metabolism and Nutrition Laboratory, INSERM U1060, Lyon-1 University, South Lyon Medical Faculty, Pierre Benite, France
S. Proschinger (491), Department for Molecular and Cellular Sports Medicine, German Sport University Cologne, Cologne, Germany
Shriram N. Rajpathak (903), Molecular Biology Research Laboratory, Department of Zoology, Savitribai Phule Pune University, Pune, India
Karyn G. Robinson (513), Tissue Engineering and Regenerative Medicine Laboratory, Alfred I. duPont Hospital for Children, Nemours Children’s Health System, Wilmington, DE, United States
Gabriela Roman (143), University of Medicine and Pharmacy; Department of Diabetes, Nutrition and Metabolic Diseases, Cluj-Napoca, Romania
Hannele Ruohola-Baker (853), Institute for Stem Cell and Regenerative Medicine; Department of Biochemistry, School of Medicine, University of Washington, Seattle, WA, United States
Adriana Rusu (143), University of Medicine and Pharmacy; Department of Diabetes, Nutrition and Metabolic Diseases, Cluj-Napoca, Romania
Kamaldeen Olalekan Sanusi (33), Department of Physiology, Faculty of Basic Medical Sciences; Centre for Advanced Medical Research and Training, Usmanu Danfodiyo University, Sokoto, Nigeria
A. Schenk (491), Institute for Sport and Sport science, TU Dortmund University, Dortmund, Germany
K.L. Seib (407), Institute for Glycomics, Griffith University, Gold Coast, QLD, Australia
Giulia Sgueglia (447), Department of Precision Medicine, University of Campania “Luigi Vanvitelli”, Naples, Italy
Liqi Shu (873), Department of Human Genetics, Emory University, Atlanta, GA, United States
J. Singh (529), Forma Therapeutics, Watertown, MA, United States
Adela Sitar-Tăut (143), University of Medicine and Pharmacy; Department of 4th Internal Medicine, ClujNapoca, Romania
Edwin Y. Soto (309), San Juan Bautista Medical School, Caguas, Puerto Rico
Ramona Suharoschi (143), University of Agricultural Sciences and Veterinary Medicine Cluj-Napoca; Molecular Nutrition and Proteomics Research Laboratory, Cluj-Napoca, Romania
J. Tajbakhsh (529), Cedars-Sinai Medical Center, Los Angeles, CA, United States
Francesco Paolo Tambaro (447), Center for Bone Marrow Transplant and Blood Transfusion, Children’s Hospital “Santobono-Pausilipon”, Naples, Italy
Julian Taranda (425), Neurology Clinic and National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany
Akshaya Thoutam (185), Division of Allergy and Immunology, Department of Internal Medicine, University of South Florida, Tampa, FL, Unites States
Trygve O. Tollefsbol (3), Distinguished Professor, Department of Biology; O’Neal Comprehensive Cancer Center; Integrative Center for Aging Research; Nutrition Obesity Research Center; Comprehensive Diabetes Center, University of Alabama at Birmingham, Birmingham, AL, United States
P. Trojer (693), Constellation Pharmaceuticals Inc., Cambridge, MA, United States
Sevin Turcan (425), Neurology Clinic and National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany
Yaaqub Abiodun Uthman (33), Department of Physiology, Faculty of Basic Medical Sciences; Centre for Advanced Medical Research and Training, Usmanu Danfodiyo University, Sokoto, Nigeria
Alexander Vaiserman (11), Laboratory of Epigenetics, D.F. Chebotarev Institute of Gerontology, NAMS, Kyiv, Ukraine
Romana Vulturar (143), University of Medicine and Pharmacy; Department of Cell and Molecular Biology, Cluj-Napoca, Romania
Huan Wang (471), Department of Food Science and Human Nutrition, University of Illinois at Urbana-Champaign, Urbana, IL; Human Genetics, David Geffen School of Medicine, University of California, Los Angeles, CA, United States
H. Wapenaar (665), Wellcome Trust Centre for Cell Biology, University of Edinburgh, Edinburgh, United Kingdom
R. Weksberg (377), Division of Clinical and Metabolic Genetics and Genetics and Genome Biology Program, The Hospital for Sick Children; Department of Pediatrics and Institute of Medical Science, University of Toronto, Toronto, ON, Canada
Junjie Xiao (919), Institute of Geriatrics (Shanghai University), Affiliated Nantong Hospital of Shanghai University (The Sixth People’s Hospital of Nantong), School of Medicine, Shanghai University, Nantong; Cardiac Regeneration and Ageing Lab, Institute of Cardiovascular Sciences, Shanghai Engineering Research Center of Organ Repair, School of Life Science, Shanghai University, Shanghai, China
Guanying Bianca Xu (471), Department of Food Science and Human Nutrition, University of Illinois at UrbanaChampaign, Urbana, IL, United States
Chang Zeng (839), Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, United States
Wei Zhang (839), Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, United States; Institute of Precision Medicine, Jining Medical University, Jining, China; The Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL, United States
Zhou Zhang (839), Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, United States
P. Zimmer (491), Institute for Sport and Sport science, TU Dortmund University, Dortmund, Germany
Preface
It has been several years since the first volume of Medical Epigenetics appeared, and a second volume is not only timely but also appropriate given the rapid developments in the areas covered in this field. The field of medical epigenetics has indeed undergone rapid growth, and the chapters contained in this new edition have been updated and revised to reflect these new changes. The first edition of Medical Epigenetics received Honorable Mention in the Clinical Medicine Award Category by the American Publishers Awards for Professional and Scholarly Excellence (PROSE) and also a “Highly Commended” Award by the British Medical Association, which attests to the high standards of this book. Many of the chapters in the second edition are authored by the same leaders in this field who contributed to the first edition of this award-winning book.
Medical Epigenetics, Second Edition provides a comprehensive analysis of the importance of epigenetics to health management. The purpose of this book is to fill a current need for a comprehensive volume on the medical aspects of epigenetics with a focus on human systems, epigenetic diseases that affect these systems, and modes of treating epigeneticbased disorders and diseases. The intent of this book is to provide a stand-alone comprehensive volume that will cover all human systems relevant to epigenetic maladies and all major aspects of medical epigenetics. The overall goal is to provide the leading book on medical epigenetics that will be useful not only to physicians, nurses, medical students, and many others directly involved with health care but also to investigators in life sciences, biotech companies, graduate students, and many others who are interested in more applied aspects of epigenetics. Research in the area of translational epigenetics is a cornerstone of this volume.
The first volume of Medical Epigenetics was published about 5 years ago, and many developments in the numerous areas of epigenetic involvement in medicine have taken place since that time. There has also been a surge of interest in precision medicine since 2015, and the second edition of Medical Epigenetics will cover this new and exciting area as well with a focus on epigenetics in precision medicine. A few areas that have not changed considerably over the 5 years or that were of lesser interest in the first edition have been removed from the second edition of Medical Epigenetics
The overall design of this book is to build from the fundamental mechanisms of epigenetics as they apply to humans to approaches for treating epigenetic-based diseases. The book begins with the basic tenets of epigenetics in human systems and progresses through general medical aspects of epigenetics, epigenetics of system disorders, multisystem medical epigenetics, pharmacology of epigenetics, and therapeutic epigenetics. The volume closes with two chapters on future prospects in medical epigenetics. It is intended that this book will be among the most comprehensive and leading books in the area of medical epigenetics and improve upon the award-winning first volume of this book.
Trygve O. Tollefsbol
